Find practical information about diabetes treatment and management, including blood sugar monitoring, medications, lifestyle changes, complications and everyday diabetes care.
The US Food and Drug Administration has expanded the use of Eli Lilly’s tirzepatide, or Mounjaro, to include lowering the risk of major cardiovascular events in adults with high-risk type 2 diabetes, based on a significant clinical trial demonstrating its…
The Met-HeFT trial reveals that metformin does not significantly lower the risk of major cardiovascular events in patients with heart failure and reduced ejection fraction, challenging previous observational data suggesting potential benefits. Metformin does not appear to reduce the risk…
SIBIONICS unveils its GS3 continuous glucose monitor at a Melbourne congress, positioning it within a broader AI-assisted diabetes management ecosystem that integrates sensor data, meal logging, and future ketone tracking. SIBIONICS used a diabetes congress in Melbourne to pitch the…
Scientists discover two coumarin-based molecules that inhibit key enzymes linked to post-meal blood sugar rises, offering potential avenues for novel diabetes therapies. Researchers reporting in Scientific Reports say they have identified two coumarin-based compounds that showed notable activity against enzymes…
Researchers at UC San Diego have unveiled a non-invasive smart ring capable of continuously measuring multiple biomarkers in finger sweat, offering real-time health insights without blood tests and promising advantages for individuals with diabetes. Engineers at the University of California…
Persistent foot wounds, such as cuts, blisters, or bruises, can be early indicators of high blood sugar levels, highlighting the importance of prompt medical attention to prevent serious complications. A small cut, blister or bruise that lingers on the foot…
The FDA has approved Abbott’s Libre Duo 10 Day, a groundbreaking wearable sensor that continuously tracks both blood glucose and ketone levels, offering earlier warning of diabetic ketoacidosis for users with diabetes aged two and above. The U.S. Food and…
A recent study challenges longstanding beliefs by pinpointing the intestine as the main target of metformin’s glucose-lowering effects, offering fresh perspectives on its mechanism and potential for personalised treatment. For decades, metformin has been the first-line medicine for many people…
A recent study reveals that type 2 diabetes may contribute to faster thinning of the brain’s cortex in older adults without cognitive impairment, raising concerns about its broader neurological impacts beyond traditional health risks. Type 2 diabetes may be doing…
Once primarily associated with diabetes and obesity, GLP-1 drugs are now being explored for their potential to treat a range of conditions including heart and kidney disease, sleep apnoea, cancer, and addiction, signalling a significant shift in their clinical use.…
Research indicates that sodium-glucose cotransporter-2 inhibitors could influence bone biology earlier than standard tests reveal, raising questions about their long-term skeletal safety. A new study in the journal Diabetes, Obesity and Metabolism adds to the debate over whether sodium-glucose cotransporter-2…
A recent review of 73,220 participants found that SGLT2 inhibitors provide consistent heart and kidney benefits across different stages of CKM syndrome, including severe cases, highlighting their potential for broader application in integrated cardiorenal care. A large review in BMC…
